Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In the words of Bjork, "It's all so quiet...sshh...sshh"
BIG WEEK HERE FELLAS!
A number of tweets were sent to these big names. Haven't yet seen any follow-up action by any of them though. Canadian PM Justin Trudeau could certainly benefit from the good PR given Revive is a small Canadian company..
Via a series of tweets over the past few days I meant. Let’s just hope some of them were actually seen by these important people of influence. We need help spreading awareness about Revive’s Bucillamine and how it can help (so that is given a fair chance and not squashed by Big Pharma) vs asking them to ‘pump’ the stock per se.
Loving that RVVTF is on the respective radars of Elon Musk, Joe Rogan, Justin Trudeau, Mark Cuban and even Conor McGregor. All being well, one or more of these important voices will leverage their popularity to spread awareness and subsequently position Bucillamine to get a fair shot vs being squashed by the influence that Big Pharma can unfortunately have. I ask Big Pharma to stand up and applaud the science here. Covid is not going away just like the common flu so best we have some highly effective therapeutics in our arsenal moving forward. For the sake of the people. Globally.
Well said. I concur. Adding regularly because I believe in the mission plus I am trusting leadership to make this a success.
Added +10k right before in anticipation of next week and the near term result. If a sell off was going to happen after yesterday's 45% climb, it would have happened today. It didn't so i think we can deduce that shares are in strong hands now for the most part.
Literally nobody cares about your trading in scraps. Wait until this suddenly rockets but you had sold for scraps. Careful son.
Excellent progress, as anticipated.
Here we go. Loading time.
This low price flabbergasts me given what is at stake and currently with the FDA. I would certainly not like to be without a very hefty position in RVVTF.
Hello cheapies!
Well said. Agree 100%. To deny the people Bucillamine in this day and age would be an absolute sin - an atrocity.
Your 1st post and it's BS. You won't do well on this forum of Longs carrying on like this, son.
Great to own both DOGE & SHIB. I certainly do as this is the best strategy IMO.
Link didn't work for me, HG. Khiron is without question one of the most undervalued stocks out there in the global MJ space. I have been accumulating down for a long time..
MindMed’s “leadership” strike me as a bunch of clueless cuntz in some key areas. I still hold my shares as I believe in the space and the mission however, you can bet on the best horse but still be stuck with the worst Jockey. In a pickle. Time will tell.
What Rick posted below merits being re-posted for anyone who does not comprehend the magnitude of this plus the appeal of SHIB as an investment.
"9/28 Top Ethereum Whale “Galion” Adds 272 Billion Shiba Inu (SHIB)".
Made many attempts to find out for certain however to no avail so far.
I concur. A conclusion did not happen with this morning's news but PANIC & FEAR certainly kicked in as a result of some investors' misinterpretation.
CEO Robert Barrow needs to step down. Kevin O'Leary needs to speak up and share with us the status of his investment in MindMed. The term "All the gear but no f#cking idea" applies to the current MindMed leadership and PR team.
Me too. 15k so far today.
A very costly misinterpretation of news today. What a buying gift to us believers.
Not selling. What drama.
Buy time. Deadly serious time this.
Agreed. An encouraging step towards that revolting fraudster being held accountable.
LOAD TIME.
It is just my personal averaging down strategy.
Shit show. Let’s all reach out to MindMed by whatever means and give them hell. Bags of potential this company & stock but they seem to have no idea how to maintain or develop investor sentiment / interest. That CEO Barrow might possess some strengths but being a well-rounded, communicative CEO is not one of them. What a weak twat this far.
If we dip below .10 I am buying another billion SHIB. Too much going on for SHIB not to. ‘Nuff said.
Yes, MindMed's leadership is weak in this regard. Very frustrating and I bet they have lost a ton more investors of late as a direct consequence. "All the gear but no f#cking idea" is the famous quote that springs to mind..
I think we are being taken for a ride by Lexaria. CEO Bunka paying himself a huge salary with still no significant revenue-generating deals. Been invested close to 3 years now and as such I no longer have faith in them. Bag holding at a hefty loss on paper which is why I am still invested.
MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances:
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects. Acute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDA.
NEW YORK, Sept. 20, 2022 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first subject has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy volunteers.
"Although amphetamines like MDMA and MDA induce mainly positive subjective and mood-enhancing effects, they may also produce negative subjective drug effects, particularly at the onset of response," said Prof. Matthias Liechti, principal investigator of the trial. "Lys-MDMA and Lys-MDA are prodrugs that are slowly metabolized to MDMA and MDA, offering a novel and controlled delivery system of these active substances with potentially improved pharmacological properties. By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA and MDA by using these prodrugs. The study will also investigate effects of MDA in direct comparison with MDMA for the first time in humans."
Dr. Miri Halperin Wernli, Executive President of MindMed, added, "This study represents an exciting opportunity to investigate the pharmacokinetic and pharmacodynamic activity of MDMA-like compounds within the same subject. Through our collaboration with the Leichti Lab at UHB, we have exclusive rights to the data from this study which will enhance our understanding of the therapeutic properties involved in the induction of positive mood in a way that may help optimize the treatment model for our R(-)-MDMA drug candidate."
The Phase 1 clinical trial is a randomized, placebo-controlled, double-blinded, 5-period crossover study. The trial plans to enroll 24 healthy subjects who will receive MDMA (100mg), MDA (93.9mg), Lys-MDMA (171.7 mg), Lys-MDA (165.6 mg), and placebo. The primary outcome measures for this study will assess acute subjective effects using Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale (0-100 percent) with higher scores representing more intense effects as well as plasma levels of MDMA and MDA at each study day across the 18-month study period. More information about the trial is available on our website (mindmed.co) or on clinicaltrials.gov (identifier NCT04847206).
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Did anyone attend the AGM or were we "NFI"?
Agree this stock is so undervalued and overlooked. This PPS is an excellent entry / add price for sure.
Easily. Predict higher given the pipeline + hype.
DOGE won't go to $0.02 - it would have already if it was possible IMO.
PPS on the rise again +7.17% right now..
BS. No-one can accurately predict anything across the crypto space. The SHIB community is strong enough to defy these analysts' BS.
I would think buying around $0.10 is a relative bargain given all the fundamentals / pending activity (if true) plus the hype. Started a pretty good position here today.